Swiss big pharma Roche has agreed to license ZW209, an experimental cancer immunotherapy from Vancouver-based Zymeworks, for ...

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...

Italy's Menarini Group will pay Maryland biotech Georgiamune $45 million (€40 million) in upfront and near-term payments, in ...

Swedish private equity firm EQT wants to acquire diagnostics specialist Qiagen for €10.8 billion, or €46.50 per share. The ...

At the IZB in Martinsried, Invitris is developing a cell-free platform to turn ­digital sequences into proteins, antibodies ...

Icelandic biotech Arctic Therapeutics has raised $21.5 million (€19.1 million) in an oversubscribed round to take two drug ...

British rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrecht.

Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule ...

The Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential ...

Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director ...

French biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial.

Over the past few years, Belgium’s argenx has become a biotech force to be reckoned with, driven by the success of its ...